This article is more than 5 years old. Information may no longer be current.
Top stories in cardiology: Sacubitril/valsartan improves health status, low-dose rivaroxaban plus aspirin may benefit heart failure
Click Here to Manage Email Alerts
Among the top stories in cardiology is a study demonstrating that sacubitril/valsartan improved quality of life and showed less frequent symptoms among patients with heart failure with reduced ejection fraction.
Patients with chronic coronary artery disease and peripheral artery disease with or without heart failure could benefit more from a combination of low-dose rivaroxaban plus aspirin.
Other stories include a study showing the major cause of death among patients with chronic heart disease without severe systolic dysfunction was sudden and/or arrhythmic death, a study showing the benefits of excluding patients with type 2 myocardial infarction from non-STEMI quality metrics and another study that found that work stress and other job strain factors increased the risk for atrial fibrillation.
Sacubitril/valsartan improves health status in real-world HFrEF cohort
In a real-world prospective cohort, patients with heart failure with reduced ejection fraction receiving sacubitril/valsartan had improved quality of life and less frequent symptoms than patients not receiving the medication, according to findings from the CHAMP-HF registry. Read More.
COMPASS: Low-dose rivaroxaban plus aspirin may benefit patients with chronic coronary artery disease, peripheral artery disease, heart failure
Patients with chronic coronary artery disease and peripheral artery disease with or without heart failure who were treated with low-dose rivaroxaban plus aspirin had reduced rates of major adverse cardiovascular events and showed a net clinical benefit compared with those treated with aspirin alone, according to a subanalysis of the COMPASS trial presented at Heart Failure 2018 & World Congress on Acute Heart Failure. Read More.
Chronic heart disease without severe systolic dysfunction increases risk for sudden, arrhythmic deaths
The major cause of death among patients with chronic heart disease without severe systolic dysfunction was sudden and/or arrhythmic death, according to a study published in JAMA Cardiology. Read More.
Differences between type 2 vs. type 1 MI may affect non-STEMI metrics
Patients with type 2 MI are different from those with type 1 MI, and it may make sense to exclude them from non-STEMI quality metrics, according to a study published in the Journal of the American Heart Association. Read More.
Job strain associated with atrial fibrillation
Work stress and other job strain factors increased the risk for atrial fibrillation, according to a study published in the European Journal of Preventive Cardiology. Read More.